KRAS ligand 5, identified by its CAS number 3043896-37-0, is a synthetic small molecule that acts as a selective modulator of the KRAS protein, which is a critical component in cell signaling pathways that regulate cell growth and differentiation. This compound is particularly significant in cancer research, as mutations in the KRAS gene are commonly associated with various types of cancers, including pancreatic, colorectal, and lung cancers. The characteristics of KRAS ligand 5 include its ability to bind specifically to the KRAS protein, potentially altering its activity and influencing downstream signaling pathways. This modulation can lead to the inhibition of tumor growth and proliferation in KRAS-driven malignancies. Additionally, the compound's chemical structure is designed to enhance its bioavailability and specificity, making it a valuable tool in the development of targeted therapies. As research continues, KRAS ligand 5 may contribute to the advancement of personalized medicine approaches in oncology, particularly for patients with KRAS mutations.

KRAS ligand 5

3043896-37-0: KRAS ligand 5, identified by its CAS number 3043896-37-0, is a synthetic small molecule that acts as a selective modulator of the KRAS protein, which is a critical component in cell signaling pathways that regulate cell growth and differentiation. This compound is particularly significant in cancer research, as mutations in the KRAS gene are commonly associated with various types of cancers, including pancreatic, colorectal, and lung cancers. The characteristics of KRAS ligand 5 include its ability to bind specifically to the KRAS protein, potentially altering its activity and influencing downstream signaling pathways. This modulation can lead to the inhibition of tumor growth and proliferation in KRAS-driven malignancies. Additionally, the compound's chemical structure is designed to enhance its bioavailability and specificity, making it a valuable tool in the development of targeted therapies. As research continues, KRAS ligand 5 may contribute to the advancement of personalized medicine approaches in oncology, particularly for patients with KRAS mutations.

<p>KRAS ligand 5 acts as the target protein ligand for PROTACK-Ras Degrader-3, which specifically targets and degrades mutated KRAS proteins.</p>

CAS 3043896-37-0

KRAS ligand 5

KRAS ligand 5

Ref: TM-T200503